Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification

作者: Semir Vranic , Snjezana Frkovic-Grazio , Janez Lamovec , Fadila Serdarevic , Olga Gurjeva

DOI: 10.1016/J.HUMPATH.2010.04.013

关键词:

摘要: Adenoid cystic carcinoma of the breast is a rare subtype cancer with basal-like features. Published studies on adenoid are limited, resulting in relatively scarce information value predictive tumor markers. We studied 20 primary cases for expression estrogen receptor, progesterone androgen epidermal growth factor HER-2/neu, and topoisomerase IIα using immunohistochemistry fluorescent situ hybridization methods. Estrogen receptor were detected 1 case each. All tumors uniformly negative Her-2/neu expression. Androgen weakly positive three 7 cases, respectively. Epidermal overexpression was 13 (65% all cases). Amplification TOP2A or HER-2/neu gene not any cases. Our study shows that majority carcinomas do overexpress Her-2/neu, IIα, thus, they unlikely to respond therapies targeting these proteins. However, frequently over-express indicating potential benefit from anti-epidermal therapy patients advanced breast.

参考文章(55)
Peter Devilee, Fattaneh A. Tavassoli, Pathology and Genetics of Tumours of the Breast and Female Genital Organs World Hhealth Organization Classification of Tumours. ,(2003)
MI Sandri, D Hochhauser, P Ayton, RC Camplejohn, R Whitehouse, H Turley, K Gatter, ID Hickson, AL Harris, Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. British Journal of Cancer. ,vol. 73, pp. 1518- 1524 ,(1996) , 10.1038/BJC.1996.286
Peter Fritz, Cristina M Cabrera, Jürgen Dippon, Andreas Gerteis, Wolfgang Simon, Walter E Aulitzky, Heiko van der Kuip, c-erbB2 and topoisomerase IIα protein expression independently predict poor survival in primary human breast cancer: a retrospective study Breast Cancer Research. ,vol. 7, pp. 1- 11 ,(2005) , 10.1186/BCR1012
Eun Y. Cho, Yoon-La Choi, Jae J. Han, Kyoung-Mee Kim, Young L. Oh, Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization. Pathology International. ,vol. 58, pp. 17- 25 ,(2007) , 10.1111/J.1440-1827.2007.02183.X
Barbara-Ann M. Millar, Marc Kerba, Bruce Youngson, Gina A. Lockwood, Fei-Fei Liu, The potential role of breast conservation surgery and adjuvant breast radiation for adenoid cystic carcinoma of the breast. Breast Cancer Research and Treatment. ,vol. 87, pp. 225- 232 ,(2004) , 10.1007/S10549-004-8693-Z
Rohit Bhargava, William L Gerald, Allan R Li, Qiulu Pan, Priti Lal, Marc Ladanyi, Beiyun Chen, EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR -activating mutations Modern Pathology. ,vol. 18, pp. 1027- 1033 ,(2005) , 10.1038/MODPATHOL.3800438
Paul M. Harari, Gregory W. Allen, James A. Bonner, Biology of Interactions: Antiepidermal Growth Factor Receptor Agents Journal of Clinical Oncology. ,vol. 25, pp. 4057- 4065 ,(2007) , 10.1200/JCO.2007.11.8984
EA Rakha, TC Putti, DM Abd El-Rehim, C Paish, AR Green, DG Powe, AH Lee, JF Robertson, IO Ellis, Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. The Journal of Pathology. ,vol. 208, pp. 495- 506 ,(2006) , 10.1002/PATH.1916
Minna Tanner, Jorma Isola, Tom Wiklund, Björn Erikstein, Pirkko Kellokumpu-Lehtinen, Per Malmström, Nils Wilking, Jonas Nilsson, Jonas Bergh, Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401. Journal of Clinical Oncology. ,vol. 24, pp. 2428- 2436 ,(2006) , 10.1200/JCO.2005.02.9264